Recombinant humanized anti-CD20 monoclonal antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant humanized anti-CD20 monoclonal antibody, covering 2025-02-10 to 2025-02-10. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy [Phase 1]